CLAIMS

1. An implant configured to fit inside the middle meatus for preventing the need for surgery in a subject who is a candidate for sinus surgery, the implant comprising a coating comprising about 7500 micrograms of mometasone furoate, the implant configured to exhibit a zero-order release for at least 60% of the mometasone furoate, characterized in that the implant is adapted to be delivered to the subject prior to surgery.

2. An implant according to Claim 1, in which the subject is to be treated for at least 4 months.

3. An implant according to Claim 1, in which the implant is configured to release 20 to 80% of the mometasone furoate during the first 12 weeks.

4. An implant according to Claim 1, in which the zero-order release is exhibited in vitro in pH 7.4 PBS buffer containing 2% SDS at 37°C.

5. An implant according to Claim 1, in which the implant is for use in a method of treating a chronic sinus condition.

6. An implant according to Claim 5, in which the chronic sinus condition is characterized by at least two symptoms selected from the group consisting of nasal obstruction, nasal congestion, difficulty breathing through nasal passages, nasal polyp, nasal discharge, and facial pain.

7. An implant according to Claim 1, in which the implant:

(a) is a braided structure;

(b) is a tubular structure;

(c) is self-expanding;

(d) has a diameter of at least 13mm; and/or

(e) has a length of at least 10mm.

8. A combination of implants for preventing the need for surgery in a subject who is a candidate for sinus surgery, comprising first and second implants, each comprising at least one coating containing about 7500 micrograms of mometasone furoate, in which the first implant is configured to fit inside a first middle meatus of the subject, the mometasone furoate

configured to have a zero-order release for more than 12 weeks; and in which the second implant is configured to fit inside a second middle meatus of the subject, the mometasone furoate configured to have a zero-order release for more than 12 weeks, characterized in that the combination is to be delivered to the subject prior to surgery, in which the subject is to be treated for at least 4 months.

9. A combination according to Claim 8, in which the subject is a candidate for Functional Endoscopic Sinus surgery (FESS).

10. A combination according to Claim 8, in which the first and second implants are configured to release 20 to 80% of the mometasone furoate during the first 12 weeks.

11. A combination according to Claim 8, in which the each of the first and second implants is configured to exhibit a zero-order release after week 1.

12. A combination according to Claim 8, in which the zero-order release is exhibited in vitro in pH 7.4 PBS buffer containing 2% SDS at 37^{o}C.

13. A combination according to Claim 8, in which the combination is for use in a method of treating a chronic sinus condition.

14. A combination according to Claim 13, in which the chronic sinus condition is characterized by at least two symptoms selected from the group consisting of nasal obstruction, nasal congestion, difficulty breathing through nasal passages, nasal polyp, nasal discharge, and facial pain.

15. A combination according to Claim 12, in which at least one of the first or second implants:

(a) is a braided structure;

(b) is a tubular structure;

(c) comprises helical strands; and/or

(d) is self-expanding.

16. A self-expanding implantable device comprising about 7500 micrograms of mometasone furoate.

17. A device according to Claim 16, in which the device:

(a) is a braided structure;

(b) is a tubular structure; and/or

(c) comprises helical strands.

18. A device according to Claim 16, in which the device comprises at least one coating, the coating containing about 7500 micrograms of mometasone furoate.

19. A device according to Claim 16, in which the device is configured to conform to the middle meatus space.

20. A combination of implants for use in the treatment of a sinus conditions, comprising first and second implants, each comprising (i) at least one drug-containing coating containing over 7500 micrograms of mometasone furoate and (ii) a topcoat layer,

in which the first implant is configured to fit inside a first middle meatus of a patient,

in which the second implant is configured to fit inside a second middle meatus of a patient,

in which the first and second implants are configured to remain implanted for at least 24 weeks.

21. A combination of implants according to Claim 20, in which at least one of the first or second implants:

(a) is a braided structure;

(b) is a tubular structure;

(c) comprises helical strands;

(d) is self-expanding; and/or

(e) is a rolled sheet.